Krensavage Asset Management, Llc

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$256K
Q ending 2026-03-31
Prior quarter
$283K
Q ending 2025-12-31
Change
-9.7% QoQ · +41.4% YoY
Positions
20
reported holdings

Largest positions

All 20 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
United Therapeutics CorpUTHRShares$50K84K
Enanta Pharmaceuticals IncENTAShares$36K2.9M
Jazz Pharmaceuticals PlcShares$32K168K
Biomarin Pharmaceutical IncBMRNShares$30K525K
Exelixis IncEXELShares$18K416K
Sanofi-AdrSNYShares$16K324K
Supernus Pharmaceuticals IncSUPNShares$15K281K
Indivior Pharmaceuticals IncINDVShares$10K340K
Ultragenyx Pharmaceutical InRAREShares$8K391K
Vanda Pharmaceuticals IncVNDAShares$8K1.2M
Embecta CorpEMBCShares$7K735K
Gsk Plc-Spon AdrGSKShares$5K97K
Biontech Se-AdrBNTXShares$5K60K
Alkermes PlcShares$4K108K
Biogen IncBIIBShares$4K20K
Regeneron PharmaceuticalsREGNShares$3K4K
Ardelyx IncARDXShares$3K500K
Inmode LtdShares$2K121K
Evolus IncEOLSShares$649158K
Abbott LaboratoriesABTShares$5135K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.